JO3434B1 - مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري - Google Patents

مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري

Info

Publication number
JO3434B1
JO3434B1 JOP/2010/0264A JOP20100264A JO3434B1 JO 3434 B1 JO3434 B1 JO 3434B1 JO P20100264 A JOP20100264 A JO P20100264A JO 3434 B1 JO3434 B1 JO 3434B1
Authority
JO
Jordan
Prior art keywords
disorders
cancer
diseases
treatment
pharmaceutical compositions
Prior art date
Application number
JOP/2010/0264A
Other languages
English (en)
Inventor
Ramanan Vijayalakshmi
D Skwierczynski Raymond
Specht Verwijs Dauntel
Sophie Tobias Irene
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42697590&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3434(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Application granted granted Critical
Publication of JO3434B1 publication Critical patent/JO3434B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Abstract

هذا الإختراع يوضح تركيبة صيدلية جديدة من مركب بالصيغة (I): (I) أو ملح مقبول صيدلياً منه الذى يكون مناسب لإنتاج أشكال صيدلية فنية، عمليات تصنيع هذه الأشكال، وإستخدام التركيبات الصيدلية لعلاج المرضى الذين يعانون من أو يتعرضون لأمراض، إضطرابات أو حالات تتضمن نجاة الخلايا، الإنقسام والهجرة، تشتمل على إضطرابات الإنقسام الإلتهابية المزمنة، إضطرابات العين، إضطرابات الإنقسام الحميدة والسرطان.
JOP/2010/0264A 2009-07-31 2010-07-26 مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري JO3434B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23021209P 2009-07-31 2009-07-31

Publications (1)

Publication Number Publication Date
JO3434B1 true JO3434B1 (ar) 2019-10-20

Family

ID=42697590

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2010/0264A JO3434B1 (ar) 2009-07-31 2010-07-26 مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري

Country Status (30)

Country Link
US (3) US20110039826A1 (ar)
EP (1) EP2459173B1 (ar)
JP (2) JP2013500965A (ar)
KR (1) KR101762285B1 (ar)
CN (2) CN102548539A (ar)
AR (1) AR077436A1 (ar)
AU (1) AU2010276741B2 (ar)
BR (1) BR112012002265B8 (ar)
CA (1) CA2769531C (ar)
CL (1) CL2012000261A1 (ar)
CO (1) CO6612185A2 (ar)
CR (1) CR20120084A (ar)
EA (1) EA025277B1 (ar)
EC (1) ECSP12011703A (ar)
GE (1) GEP201606513B (ar)
IL (1) IL217839A (ar)
IN (1) IN2012DN01237A (ar)
JO (1) JO3434B1 (ar)
MA (1) MA33533B1 (ar)
MX (2) MX2012001196A (ar)
MY (1) MY174084A (ar)
NZ (1) NZ598096A (ar)
PE (1) PE20120788A1 (ar)
SG (2) SG10201404483VA (ar)
TN (1) TN2012000046A1 (ar)
TW (1) TWI522357B (ar)
UA (1) UA110463C2 (ar)
UY (1) UY32822A (ar)
WO (1) WO2011014248A1 (ar)
ZA (1) ZA201200944B (ar)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE381566T1 (de) * 2004-05-14 2008-01-15 Millennium Pharm Inc Verbindungen und verfahren zur inhibierung der mitotischen progression durch hemmung von aurorakinase
US20100183601A1 (en) 2008-12-22 2010-07-22 Millennium Pharmaceuticals, Inc. Combination of Aurora Kinase Inhibitors and Anti-CD20 Antibodies
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
TWI392514B (zh) * 2010-01-29 2013-04-11 Colgate Palmolive Co 具有高微生物效力之不含氟化物及陰離子表面活性劑的潔牙劑
CN104031049A (zh) 2010-02-19 2014-09-10 米伦纽姆医药公司 极光激酶抑制剂的结晶形式
AR086656A1 (es) 2011-06-03 2014-01-15 Millennium Pharm Inc Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
EP2976086B1 (en) 2013-03-22 2020-10-14 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
JP6525474B2 (ja) 2013-12-06 2019-06-05 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼ阻害剤と抗ｃｄ３０抗体の併用
USD797120S1 (en) 2015-08-28 2017-09-12 Samsung Electronics Co., Ltd. Display screen or portion thereof with graphical user interface

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747487A (en) * 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US6057329A (en) 1996-12-23 2000-05-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives
CN101259270A (zh) 1999-08-11 2008-09-10 拜奥根Idec公司 用抗cd20抗体治疗累及骨髓的非霍奇金淋巴瘤患者
KR20030019327A (ko) * 2000-03-24 2003-03-06 아이박스 리서치 인코포레이티드 탁산-기저 조성물을 안정시키는 금속염의 용도
US6982253B2 (en) * 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
ATE381566T1 (de) * 2004-05-14 2008-01-15 Millennium Pharm Inc Verbindungen und verfahren zur inhibierung der mitotischen progression durch hemmung von aurorakinase
US20070104785A1 (en) * 2005-07-29 2007-05-10 Navale Suryakant V Tablets of linezolid form iii and processes for their preparation
SI1962830T1 (sl) * 2005-12-23 2013-07-31 Glaxosmithkline Llc Azaindolni inhibitorji kinaz Aurora
CN101511361A (zh) 2006-06-30 2009-08-19 先灵公司 使用增强p53活性的取代哌啶的方法
CN101516335B (zh) * 2006-07-21 2014-01-08 诺瓦提斯公司 苯并咪唑基吡啶基醚的制剂
US7718648B2 (en) 2006-08-09 2010-05-18 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
CL2007003244A1 (es) * 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
US20090203671A1 (en) * 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
US20100183601A1 (en) * 2008-12-22 2010-07-22 Millennium Pharmaceuticals, Inc. Combination of Aurora Kinase Inhibitors and Anti-CD20 Antibodies
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
CN104031049A (zh) * 2010-02-19 2014-09-10 米伦纽姆医药公司 极光激酶抑制剂的结晶形式

Also Published As

Publication number Publication date
CR20120084A (es) 2012-06-01
CN102548539A (zh) 2012-07-04
EP2459173B1 (en) 2018-02-28
SG177751A1 (en) 2012-02-28
NZ598096A (en) 2014-05-30
KR101762285B1 (ko) 2017-07-28
US9127011B2 (en) 2015-09-08
MY174084A (en) 2020-03-09
ZA201200944B (en) 2015-07-29
SG10201404483VA (en) 2014-10-30
US20140073630A1 (en) 2014-03-13
US9504693B2 (en) 2016-11-29
TN2012000046A1 (en) 2013-09-19
CO6612185A2 (es) 2013-02-01
AU2010276741A1 (en) 2012-03-01
CN103893186A (zh) 2014-07-02
ECSP12011703A (es) 2012-03-30
MX2012001196A (es) 2012-03-14
WO2011014248A1 (en) 2011-02-03
CA2769531C (en) 2017-11-07
MA33533B1 (ar) 2012-08-01
CA2769531A1 (en) 2011-02-03
BR112012002265B1 (pt) 2021-01-12
CN103893186B (zh) 2019-07-09
AR077436A1 (es) 2011-08-24
IN2012DN01237A (ar) 2015-05-15
KR20120053008A (ko) 2012-05-24
EP2459173A1 (en) 2012-06-06
BR112012002265A2 (pt) 2016-06-14
GEP201606513B (en) 2016-07-25
EA025277B1 (ru) 2016-12-30
UY32822A (es) 2011-01-31
EA201270205A1 (ru) 2012-07-30
US20160158244A1 (en) 2016-06-09
PE20120788A1 (es) 2012-07-22
US20110039826A1 (en) 2011-02-17
CL2012000261A1 (es) 2012-08-03
IL217839A0 (en) 2012-03-29
BR112012002265B8 (pt) 2021-05-25
TW201107331A (en) 2011-03-01
MX348197B (es) 2017-06-05
JP2015091877A (ja) 2015-05-14
JP6014695B2 (ja) 2016-10-25
IL217839A (en) 2017-01-31
TWI522357B (zh) 2016-02-21
JP2013500965A (ja) 2013-01-10
UA110463C2 (ru) 2016-01-12
AU2010276741B2 (en) 2016-07-14

Similar Documents

Publication Publication Date Title
TN2012000046A1 (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorfers
MX2013012588A (es) Inhibidores de cinasa.
EA031157B9 (ru) Вводимая перорально кортикостероидная композиция
NZ608116A (en) Triazine-oxadiazoles
MX2009006543A (es) Compuestos heterociclicos y su uso en el tratamiento de la inflamacion, angiogenesis y cancer.
MX2010007683A (es) Derivados heterociclicos fusionados y metodos de uso como inhibidores de c-met.
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
MX2009009153A (es) Pirano-pirazol-aminas.
EA201171088A1 (ru) Лечение дискинезии при различных расстройствах
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
GEP20135806B (en) Lactams as beta secretase inhibitors
MX360554B (es) Composiciones que comprenden y metodos que utilizan inhibidores de co-transportadores de glucosa-sodio 1 y 2.
MX2009009154A (es) Derivados de espiro-pirano-pirazol.
IN2012DN03042A (ar)
MX2012013879A (es) Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.
MX2014002394A (es) Inhibidores de rock suaves, novedosos.
MX2013006768A (es) Moduladores de receptor de glucagon.
MX2011012384A (es) Derivados nitrilo y sus usos y composiciones farmaceuticas.
IN2013DN02555A (ar)
MX2014003584A (es) Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides.
MY182553A (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
MX2014003455A (es) Derivados de metanosulfonamida sustituidos con arilo o n-heteroarilo como ligandos de receptor vanilloide.
MX2011008857A (es) Derivados de oxiindol con actividad agonistica del receptor de motilina.
MX2010004620A (es) Derivados de benzomorfolina y metodos de uso.